Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib, Toripalimab, and Chemotherapy in Advanced Non-squamous NSCLC
NCT05003037Phase 2Active, not recruiting
- Start
- Jan 2022
- Primary completion
- Nov 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of surufatinib and toripalimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms). Primary endpoint: Progression Free Survival up to 24 months. Started Jan 2022; status: active, not recruiting.
02
Drugs
surufatinibtoripalimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05003037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003037.